超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Plexxikon
Plexxikon公司是結構導向發現領域和治療人類疾病的新型小分子藥品開發領域的領導者。該公司的先導化合物PLX4032用于治療黑色素瘤，正在進行后期臨床試驗。該公司正在開發的臨床期和臨床前期化合物陣容致力于滿足心臟-腎臟疾病、中樞神經系統障礙、自身免疫性和神經炎性疾病以及腫瘤領域未獲滿足的醫療需求。Plexxikon公司專利擁有的Scaffold-Based Drug Discovery? 平臺整合了多種一流技術，包括結構篩選，該關鍵部件相對于其他藥物發現方法具有顯著的競爭優勢

Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical and preclinical stage programs in a number of therapeutic areas, including cardio-renal disease, CNS, inflammation, metabolic disease and oncology. Plexxikon’s most advanced program, PLX4032, is currently in pivotal, late-stage clinical trials for the treatment of melanoma. With an option to co-promote PLX4032 in the U.S. as well as a pipeline of oncology opportunities, Plexxikon is laying the foundation for its first commercial franchise—in oncology. Other clinical stage programs include drug candidates for metastatic cancer, polycystic kidney disease, diabetes and rheumatoid arthritis. Plexxikon is uniquely positioned to develop multiple commercial franchises for different therapeutic indications, and build significant value for Plexxikon, its collaborators and investors.

Plexxikon's unique discovery approach, combined with an experienced management and scientific team, a broad network of scientific and clinical experts, and partnership deals that secure near term funding and retain significant commercial rights, have been key drivers of the company's success since it began operations in 2001.

With its Scaffold-Based Drug Discovery Platform?, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process in conjunction with a highly specialized scaffold-like screening library, to design new drug candidates within various families of drug targets. This systematic, cost-efficient approach allows Plexxikon to leverage its target-specific chemistry investment for multiple targets within a given family. Additionally, Plexxikon’s platform has proven particularly amenable to the design of highly selective kinase inhibitors. This selectivity has enhanced the safety profile of its targeted drugs.